{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Ovarian+Cancer+AJCC+v6+and+v7&page=2",
    "query": {
      "condition": "Stage IV Ovarian Cancer AJCC v6 and v7",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Ovarian+Cancer+AJCC+v6+and+v7&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:12:45.834Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01372787",
      "title": "Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Anxiety",
        "Fatigue",
        "Nausea and Vomiting",
        "Neurotoxicity Syndrome",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Stage I Ovarian Cancer AJCC v6 and v7",
        "Stage IA Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IB Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IC Fallopian Tube Cancer AJCC v6 and v7",
        "Stage II Ovarian Cancer AJCC v6 and v7",
        "Stage IIA Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIB Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIC Fallopian Tube Cancer AJCC v6 and v7",
        "Stage III Ovarian Cancer AJCC v6 and v7",
        "Stage III Primary Peritoneal Cancer AJCC v7",
        "Stage IIIA Fallopian Tube Cancer AJCC v7",
        "Stage IIIB Fallopian Tube Cancer AJCC v7",
        "Stage IIIC Fallopian Tube Cancer AJCC v7",
        "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Primary Peritoneal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Assessment of Therapy Complications",
          "type": "PROCEDURE"
        },
        {
          "name": "Medical Chart Review",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 103,
      "start_date": "2011-04-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2019-03-12",
      "last_synced_at": "2026-05-22T03:12:45.834Z",
      "location_count": 144,
      "location_summary": "Aurora, Colorado • Hartford, Connecticut • New Britain, Connecticut + 105 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01372787"
    },
    {
      "nct_id": "NCT01970722",
      "title": "Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "FIGO Stage IVA Ovarian Cancer",
        "FIGO Stage IVB Ovarian Cancer",
        "Platinum-Resistant Ovarian Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Uterine Corpus Carcinoma",
        "Stage III Fallopian Tube Cancer AJCC v7",
        "Stage III Ovarian Cancer AJCC v6 and v7",
        "Stage III Primary Peritoneal Cancer AJCC v7",
        "Stage III Uterine Corpus Cancer AJCC v7",
        "Stage IIIA Fallopian Tube Cancer AJCC v7",
        "Stage IIIA Ovarian Cancer AJCC v6 and v7",
        "Stage IIIA Primary Peritoneal Cancer AJCC v7",
        "Stage IIIA Uterine Corpus Cancer AJCC v7",
        "Stage IIIB Fallopian Tube Cancer AJCC v7",
        "Stage IIIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIIB Primary Peritoneal Cancer AJCC v7",
        "Stage IIIB Uterine Corpus Cancer AJCC v7",
        "Stage IIIC Fallopian Tube Cancer AJCC v7",
        "Stage IIIC Ovarian Cancer AJCC v6 and v7",
        "Stage IIIC Primary Peritoneal Cancer AJCC v7",
        "Stage IIIC Uterine Corpus Cancer AJCC v7",
        "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Primary Peritoneal Cancer AJCC v7",
        "Stage IV Uterine Corpus Cancer AJCC v7",
        "Stage IVA Uterine Corpus Cancer AJCC v7",
        "Stage IVB Uterine Corpus Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2014-05-19",
      "completion_date": "2027-01-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-05-22T03:12:45.834Z",
      "location_count": 4,
      "location_summary": "Corona, California • Duarte, California • Upland, California + 1 more",
      "locations": [
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01970722"
    },
    {
      "nct_id": "NCT05334069",
      "title": "Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Ann Arbor Stage I Lymphoma",
        "Ann Arbor Stage II Lymphoma",
        "Ann Arbor Stage III Lymphoma",
        "Ann Arbor Stage IV Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Chronic Myeloid Leukemia",
        "Gastroesophageal Junction Adenocarcinoma",
        "Head and Neck Carcinoma",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Invasive Breast Carcinoma",
        "Kidney Carcinoma",
        "Malignant Hepatobiliary Neoplasm",
        "Malignant Solid Neoplasm",
        "Melanoma",
        "Muscle-Invasive Bladder Carcinoma",
        "RISS Stage I Plasma Cell Myeloma",
        "RISS Stage II Plasma Cell Myeloma",
        "RISS Stage III Plasma Cell Myeloma",
        "Sarcoma",
        "Stage I Bladder Cancer AJCC v6 and v7",
        "Stage I Breast Cancer AJCC v7",
        "Stage I Colorectal Cancer AJCC v6 and v7",
        "Stage I Esophageal Cancer AJCC V7",
        "Stage I Gastric Cancer AJCC V7",
        "Stage I Lung Cancer AJCC v7",
        "Stage I Ovarian Cancer AJCC v6 and v7",
        "Stage I Pancreatic Cancer AJCC v6 and v7",
        "Stage I Prostate Cancer AJCC v7",
        "Stage I Uterine Corpus Cancer AJCC v7",
        "Stage II Bladder Cancer AJCC v6 and v7",
        "Stage II Breast Cancer AJCC v6 and v7",
        "Stage II Colorectal Cancer AJCC v7",
        "Stage II Esophageal Cancer AJCC v7",
        "Stage II Gastric Cancer AJCC v7",
        "Stage II Lung Cancer AJCC v7",
        "Stage II Ovarian Cancer AJCC v6 and v7",
        "Stage II Pancreatic Cancer AJCC v6 and v7",
        "Stage II Prostate Cancer AJCC v7",
        "Stage II Uterine Corpus Cancer AJCC v7",
        "Stage III Bladder Cancer AJCC v6 and v7",
        "Stage III Breast Cancer AJCC v7",
        "Stage III Colorectal Cancer AJCC v7",
        "Stage III Esophageal Cancer AJCC v7",
        "Stage III Gastric Cancer AJCC v7",
        "Stage III Lung Cancer AJCC v7",
        "Stage III Ovarian Cancer AJCC v6 and v7",
        "Stage III Pancreatic Cancer AJCC v6 and v7",
        "Stage III Prostate Cancer AJCC v7",
        "Stage III Uterine Corpus Cancer AJCC v7",
        "Stage IV Bladder Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Colorectal Cancer AJCC v7",
        "Stage IV Esophageal Cancer AJCC v7",
        "Stage IV Gastric Cancer AJCC v7",
        "Stage IV Lung Cancer AJCC v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Pancreatic Cancer AJCC v6 and v7",
        "Stage IV Prostate Cancer AJCC v7",
        "Stage IV Uterine Corpus Cancer AJCC v7",
        "Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 2000,
      "start_date": "2022-08-18",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-05-22T03:12:45.834Z",
      "location_count": 746,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 501 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05334069"
    },
    {
      "nct_id": "NCT02659241",
      "title": "Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Advanced Fallopian Tube Carcinoma",
        "Advanced Ovarian Carcinoma",
        "Advanced Primary Peritoneal Carcinoma",
        "Carcinomatosis",
        "Fallopian Tube High Grade Serous Adenocarcinoma",
        "Ovarian High Grade Serous Adenocarcinoma",
        "Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Stage III Fallopian Tube Cancer AJCC v7",
        "Stage III Ovarian Cancer AJCC v6 and v7",
        "Stage III Primary Peritoneal Cancer AJCC v7",
        "Stage IIIA Fallopian Tube Cancer AJCC v7",
        "Stage IIIA Ovarian Cancer AJCC v6 and v7",
        "Stage IIIA Primary Peritoneal Cancer AJCC v7",
        "Stage IIIB Fallopian Tube Cancer AJCC v7",
        "Stage IIIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIIB Primary Peritoneal Cancer AJCC v7",
        "Stage IIIC Fallopian Tube Cancer AJCC v7",
        "Stage IIIC Ovarian Cancer AJCC v6 and v7",
        "Stage IIIC Primary Peritoneal Cancer AJCC v7",
        "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Primary Peritoneal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Adavosertib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 38,
      "start_date": "2016-02-04",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-05-22T03:12:45.834Z",
      "location_count": 8,
      "location_summary": "Portland, Oregon • Conroe, Texas • Houston, Texas + 2 more",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Conroe",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02659241"
    },
    {
      "nct_id": "NCT02726997",
      "title": "Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stage III Fallopian Tube Cancer AJCC v7",
        "Stage III Ovarian Cancer AJCC v6 and v7",
        "Stage III Primary Peritoneal Cancer AJCC v7",
        "Stage IIIA Fallopian Tube Cancer AJCC v7",
        "Stage IIIA Ovarian Cancer AJCC v6 and v7",
        "Stage IIIA Primary Peritoneal Cancer AJCC v7",
        "Stage IIIB Fallopian Tube Cancer AJCC v7",
        "Stage IIIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIIB Primary Peritoneal Cancer AJCC v7",
        "Stage IIIC Fallopian Tube Cancer AJCC v7",
        "Stage IIIC Ovarian Cancer AJCC v6 and v7",
        "Stage IIIC Primary Peritoneal Cancer AJCC v7",
        "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Primary Peritoneal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2016-07-06",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-05-22T03:12:45.834Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02726997"
    },
    {
      "nct_id": "NCT01081262",
      "title": "Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Borderline Ovarian Mucinous Tumor",
        "Ovarian Mucinous Cystadenocarcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Stage IA Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IA Ovarian Cancer AJCC v6 and v7",
        "Stage IB Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IB Ovarian Cancer AJCC v6 and v7",
        "Stage IC Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IC Ovarian Cancer AJCC v6 and v7",
        "Stage IIA Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIA Ovarian Cancer AJCC V6 and v7",
        "Stage IIB Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIC Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIC Ovarian Cancer AJCC v6 and v7",
        "Stage IIIA Fallopian Tube Cancer AJCC v7",
        "Stage IIIA Ovarian Cancer AJCC v6 and v7",
        "Stage IIIB Fallopian Tube Cancer AJCC v7",
        "Stage IIIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIIC Fallopian Tube Cancer AJCC v7",
        "Stage IIIC Ovarian Cancer AJCC v6 and v7",
        "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2010-10-12",
      "completion_date": "2027-03-12",
      "has_results": true,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-05-22T03:12:45.834Z",
      "location_count": 248,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 163 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01081262"
    },
    {
      "nct_id": "NCT00108745",
      "title": "Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Fallopian Tube Endometrioid Adenocarcinoma",
        "Fallopian Tube Mucinous Adenocarcinoma",
        "Fallopian Tube Serous Adenocarcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Fallopian Tube Undifferentiated Carcinoma",
        "Ovarian Brenner Tumor",
        "Ovarian Clear Cell Adenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Seromucinous Carcinoma",
        "Ovarian Serous Adenocarcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Ovarian Undifferentiated Carcinoma",
        "Primary Peritoneal Serous Adenocarcinoma",
        "Stage IIIA Fallopian Tube Cancer AJCC v7",
        "Stage IIIA Ovarian Cancer AJCC v6 and v7",
        "Stage IIIA Primary Peritoneal Cancer AJCC v7",
        "Stage IIIB Fallopian Tube Cancer AJCC v7",
        "Stage IIIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIIB Primary Peritoneal Cancer AJCC v7",
        "Stage IIIC Fallopian Tube Cancer AJCC v7",
        "Stage IIIC Ovarian Cancer AJCC v6 and v7",
        "Stage IIIC Primary Peritoneal Cancer AJCC v7",
        "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Primary Peritoneal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Clinical Observation",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel Poliglumex",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "GOG Foundation",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 1157,
      "start_date": "2005-03-21",
      "completion_date": "2022-02-22",
      "has_results": true,
      "last_update_posted_date": "2021-09-30",
      "last_synced_at": "2026-05-22T03:12:45.834Z",
      "location_count": 315,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 228 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00108745"
    },
    {
      "nct_id": "NCT02208375",
      "title": "mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "BRCA1 Mutation Carrier",
        "BRCA2 Mutation Carrier",
        "Endometrial Adenocarcinoma",
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "High Grade Ovarian Serous Adenocarcinoma",
        "Progesterone Receptor Negative",
        "Recurrent Breast Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Uterine Corpus Carcinoma",
        "Stage III Uterine Corpus Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Uterine Corpus Cancer AJCC v7",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Vistusertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 159,
      "start_date": "2014-11-11",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-05-22T03:12:45.834Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02208375"
    },
    {
      "nct_id": "NCT02142803",
      "title": "TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Glioblastoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Ovarian Clear Cell Cystadenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mucinous Cystadenocarcinoma",
        "Ovarian Serous Cystadenocarcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Malignant Uterine Corpus Neoplasm",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Solid Neoplasm",
        "Stage IIIA Fallopian Tube Cancer AJCC v7",
        "Stage IIIA Ovarian Cancer AJCC v6 and v7",
        "Stage IIIA Primary Peritoneal Cancer AJCC v7",
        "Stage IIIB Fallopian Tube Cancer AJCC v7",
        "Stage IIIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIIB Primary Peritoneal Cancer AJCC v7",
        "Stage IIIC Fallopian Tube Cancer AJCC v7",
        "Stage IIIC Ovarian Cancer AJCC v6 and v7",
        "Stage IIIC Primary Peritoneal Cancer AJCC v7",
        "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Primary Peritoneal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2014-05-20",
      "completion_date": "2026-10-16",
      "has_results": true,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-05-22T03:12:45.834Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Charlestown, Massachusetts • Columbus, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02142803"
    },
    {
      "nct_id": "NCT03902379",
      "title": "Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Endometrial Carcinoma",
        "Stage 0 Fallopian Tube Cancer AJCC v7",
        "Stage I Fallopian Tube Cancer AJCC v6 and v7",
        "Stage I Ovarian Cancer AJCC v6 and v7",
        "Stage IA Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IA Ovarian Cancer AJCC v6 and v7",
        "Stage IB Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IB Ovarian Cancer AJCC v6 and v7",
        "Stage IC Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IC Ovarian Cancer AJCC v6 and v7",
        "Stage II Cervical Cancer AJCC v7",
        "Stage II Fallopian Tube Cancer AJCC v6 and v7",
        "Stage II Ovarian Cancer AJCC v6 and v7",
        "Stage II Uterine Corpus Cancer AJCC v7",
        "Stage IIA Cervical Cancer AJCC v7",
        "Stage IIA Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIA Ovarian Cancer AJCC V6 and v7",
        "Stage IIA1 Cervical Cancer AJCC v7",
        "Stage IIA2 Cervical Cancer AJCC v7",
        "Stage IIB Cervical Cancer AJCC v6 and v7",
        "Stage IIB Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIC Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIC Ovarian Cancer AJCC v6 and v7",
        "Stage III Cervical Cancer AJCC v6 and v7",
        "Stage III Fallopian Tube Cancer AJCC v7",
        "Stage III Ovarian Cancer AJCC v6 and v7",
        "Stage III Primary Peritoneal Cancer AJCC v7",
        "Stage III Uterine Corpus Cancer AJCC v7",
        "Stage IIIA Cervical Cancer AJCC v6 and v7",
        "Stage IIIA Fallopian Tube Cancer AJCC v7",
        "Stage IIIA Ovarian Cancer AJCC v6 and v7",
        "Stage IIIA Primary Peritoneal Cancer AJCC v7",
        "Stage IIIA Uterine Corpus Cancer AJCC v7",
        "Stage IIIB Cervical Cancer AJCC v6 and v7",
        "Stage IIIB Fallopian Tube Cancer AJCC v7",
        "Stage IIIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIIB Primary Peritoneal Cancer AJCC v7",
        "Stage IIIB Uterine Corpus Cancer AJCC v7",
        "Stage IIIC Fallopian Tube Cancer AJCC v7",
        "Stage IIIC Ovarian Cancer AJCC v6 and v7",
        "Stage IIIC Primary Peritoneal Cancer AJCC v7",
        "Stage IIIC Uterine Corpus Cancer AJCC v7",
        "Stage IIIC1 Uterine Corpus Cancer AJCC v7",
        "Stage IIIC2 Uterine Corpus Cancer AJCC v7",
        "Stage IV Cervical Cancer AJCC v6 and v7",
        "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Primary Peritoneal Cancer AJCC v7",
        "Stage IV Uterine Corpus Cancer AJCC v7",
        "Stage IVA Cervical Cancer AJCC v6 and v7",
        "Stage IVA Uterine Corpus Cancer AJCC v7",
        "Stage IVB Cervical Cancer AJCC v6 and v7",
        "Stage IVB Uterine Corpus Cancer AJCC v7",
        "Uterine Carcinosarcoma",
        "Uterine Corpus Sarcoma"
      ],
      "interventions": [
        {
          "name": "Internet-Based Intervention",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2016-07-27",
      "completion_date": "2020-05-31",
      "has_results": false,
      "last_update_posted_date": "2021-04-19",
      "last_synced_at": "2026-05-22T03:12:45.834Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03902379"
    }
  ]
}